H.C. Wainwright Initiates a Hold Rating on Radius Health (RDUS)


Radius Health (RDUS) received a Hold rating and a $22 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed yesterday at $19.17.

Tsao noted:

“Valuation Our $22 price target for Radius is based on our sum of the parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 10.1% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%).”

According to TipRanks.com, Tsao is ranked #2794 out of 5163 analysts.

The word on The Street in general, suggests a Hold analyst consensus rating for Radius Health with a $22 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $40.97 and a one-year low of $12.81. Currently, Radius Health has an average volume of 675.8K.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The firm’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts